Reauthorizes the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031.
The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends the provisions of the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031. It mandates the Food and Drug Administration (FDA) to request interim clinical trial data from drug manufacturers to assess investigational drugs. The bill also requires the FDA to publish a report on the status of the 2022 Action Plan for rare neurodegenerative diseases, including ALS, and to develop an updated action plan.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.